Which group would benefit from applying the ICER framework to genetic interventions?

The ICER framework, which stands for the Institute for Clinical and Economic Review, is primarily focused on evaluating the value of medical interventions in terms of their clinical effectiveness and cost-effectiveness. This approach combines clinical data with economic analysis to determine whether a health intervention provides sufficient value relative to its costs.

By applying the ICER framework to genetic interventions, policy makers in healthcare can assess the utility of these interventions in terms of both their health outcomes and financial implications. This evaluation is particularly important as genetic testing and therapies can often be expensive. Understanding the cost-effectiveness helps in making informed decisions regarding coverage, funding, and accessibility of these interventions.

This decision-making process is critical to allocate resources efficiently and ensure that the healthcare system can support the adoption of effective genetic interventions while maintaining overall sustainability. In contrast, while the other groups mentioned may have an interest in genetic interventions, their functions do not align with the focus of economic evaluation and policy implementation as directly as those of healthcare policy makers.